NEW YORK (GenomeWeb) – Silence Therapeutics this week announced that it has completed patient recruitment for a Phase IIa trial of its siRNA-based cancer drug Atu027.
In the study, the drug is being tested in combination with gemcitabine in 24 patients with locally advanced or metastatic pancreatic adenocarcinoma. Data from the study are expected in mid-2015.